Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(OP:
LOBEF
)
0.0250
+0.0019 (+8.23%)
Streaming Delayed Price
Updated: 9:36 AM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
149,201
Open
0.0250
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0231
Today's Range
0.0210 - 0.0255
52wk Range
0.0082 - 0.0319
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
June 17, 2025
Via
ACCESS Newswire
Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
June 03, 2025
Via
ACCESS Newswire
Performance
YTD
+25.0%
+25.0%
1 Month
+42.0%
+42.0%
3 Month
+8.7%
+8.7%
6 Month
+47.1%
+47.1%
1 Year
+66.7%
+66.7%
More News
Read More
Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
April 14, 2025
Via
ACCESS Newswire
Lobe Sciences Provides Corporate Update
April 04, 2025
Via
ACCESS Newswire
Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
November 18, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
October 16, 2024
From
Lobe Sciences, Ltd.
Via
Business Wire
Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
October 02, 2024
From
Lobe Sciences, Ltd.
Via
Business Wire
Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
August 15, 2024
From
Lobe Sciences Ltd
Via
Business Wire
Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
August 12, 2024
From
Lobe Sciences Ltd
Via
Business Wire
Lobe Sciences Announces Update
June 04, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
June 03, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
May 31, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
May 30, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
May 21, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Via
Benzinga
Lobe Sciences Provides Company Review of 2023
January 08, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Provides Update on L-130 Clinical Program
December 07, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
December 05, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
September 14, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
Via
Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
June 28, 2023
Via
Benzinga
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
June 27, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer
June 07, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™
May 17, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
Via
Benzinga
Frequently Asked Questions
Is LOBEF publicly traded?
Yes, LOBEF is publicly traded.
What exchange does LOBEF trade on?
LOBEF trades on the OTC Traded
What is the ticker symbol for LOBEF?
The ticker symbol for LOBEF is LOBEF on the OTC Traded
What is the current price of LOBEF?
The current price of LOBEF is 0.0250
When was LOBEF last traded?
The last trade of LOBEF was at 07/03/25 09:36 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.